Embedded Files
Post date: Mar 10, 2016 1:57:15 AM
Professor Charles R. CANTOR, who was the mentor of Prof. Kang in his PhD degree course at Columbia University, is visiting KAIST and giving a lecture in the Department of Biological Sciences Seminar on April 30th (Tuesday).
“Noninvasive Personalized Genomics” by Prof. Charles R. Cantor
Abstract: Variations in the sequence of DNA, or the abundance of particular DNA sequences are the root cause of many human diseases. It is not surprising that methods that can assess these variations with high precision can provide diagnostic tests or clinical evaluations with high specificity and sensitivity. The choice of analytical tool to study DNA in clinical samples depends on the complexity of the sequence changes that must be measured. For a single gene or variation like a single nucleotide polymorphism, conventional quantitative PCR (polymerase chain reaction) analysis often suffices. For problems where tens to hundreds of markers or loci must be examined, nucleic acid mass spectrometry is ideal. Where larger numbers of markers are relevant, or where the entire genome must be scanned, the only currently deployable method is second generation DNA sequencing. Further tradeoffs among these methods can be affected by low abundance samples, or rare sequences, by costs and by deployability. In this talk I will show examples of diagnostic tests based on mass spectrometry and second generation DNA sequencing and I will discuss recent research results that indicate the kinds of tests that are likely to reach the clinic in the next few years. Applications will include carrier screening, ophthalmology, cancer, and prenatal testing.
Professor Charles R. Cantor, Ph.D. is a founder, and Chief Scientific Officer at SEQUENOM, Inc. He is also founder of SelectX Pharmaceuticals, a drug discovery company based in the Boston area; Retrotope, an anti-aging company; and DiThera, a biotherapeutic company. He is co-director of the Center for Advanced Biotechnology at Boston University, and professor emeritus of Biomedical Engineering. Dr. Cantor has held positions at Columbia University and University of California at Berkeley, and was also director of the Human Genome Center of the Department of Energy at Lawrence Berkeley Laboratory. He has published more than 450 peer-reviewed articles, has been granted more than 60 patents. He co-authored a three-volume textbook on Biophysical Chemistry and the first textbook on Genomics: The Science and Technology of the Human Genome Project. He sits on the advisory boards of more than 15 national and international organizations and is a member of the National Academy of Sciences.
Contact: Prof. Changwon Kang at 042-350-2628
Page updated
Report abuse